940879-09-4

Basic information

• Product Name: (2R)-2-(phenylcarbonyloxy)propyl (2S)-2-(tert-butoxycarbonyl)amino-3-(3,4-dihydroxyphenyl)propanoate
• Synonyms: (2R)-2-(phenylcarbonyloxy)propyl (2S)-2-(tert-butoxycarbonyl)amino-3-(3,4-dihydroxyphenyl)propanoate
• CAS NO: 940879-09-4
• Molecular Weight: 459.496
• Mol File: 940879-09-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2R)-2-(phenylcarbonyloxy)propyl (2S)-2-(tert-butoxycarbonyl)amino-3-(3,4-dihydroxyphenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-2-(phenylcarbonyloxy)propyl (2S)-2-(tert-butoxycarbonyl)amino-3-(3,4-dihydroxyphenyl)propanoate(940879-09-4)
• EPA Substance Registry System: (2R)-2-(phenylcarbonyloxy)propyl (2S)-2-(tert-butoxycarbonyl)amino-3-(3,4-dihydroxyphenyl)propanoate(940879-09-4)

Safety Data

• Hazardous Substances Data: 940879-09-4(Hazardous Substances Data)

Upstream product

• 871580-90-4 (1R)-2-bromo-1-methylethyl benzoate 
• 940879-11-8 (2S)-3-(3,4-dihydroxyphenyl)-2-[(tert-butoxycarbonyl)amino]propanoic acid tetrabutylammonium salt 
• 188663-13-0 benzaldehyde (2R)-propylene glycol acetal 
• 100-52-7 benzaldehyde 
• 15519-28-5 cesium bicarbonate 
• 30033-24-0 (2S)-3-(3,4-dihydroxyphenyl)-2-[(tert-butoxy)carbonylamino]propanoic acid 

Downstream Products

• 940879-06-1 (2R)-2-(phenylcarbonyloxy)propyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate 

Relevant articles and documents

PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF A LEVODOPA PRODRUG AND METHODS OF USE

Pharmaceutical compositions and oral dosage forms of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and methods of treating diseases comprising orally administering such pharmaceutical compositions and dosage forms

Methods of Synthesizing a Levodopa Ester Prodrug

Methods of synthesizing a levodopa ester prodrug, salts thereof, and synthetic intermediates thereof are disclosed.

Levodopa prodrug mesylate, compositions thereof, and uses thereof

(2R)-2-Phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parki